



1616
JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Clarence N. Ahlem, et al.
Application No. : 10/087,929
Filed : March 1, 2002
Title : Blood Cell Deficiency Treatment Method
Examiner : Sabiha N. Qazi
TC/A.U. : 1616

Docket No. : 202.8
Customer No. : 26551
Confirmation No. : 7989

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT TRANSMITTAL

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 (in duplicate) listing references (37). A copy of foreign patent documents and other documents are enclosed. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b). Please charge any fees due or credit any overpayments to **Deposit Account No. 501536**. A duplicate copy of this sheet is enclosed.

Please direct all correspondence to **Customer No. 26,551**.

Respectfully submitted,

HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated: Aug. 9, 2004

By: Daryl D. Muenchau
Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, California, 92121
Telephone: (858) 587-9333
Customer No. 26,551



Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


CERTIFICATE OF MAILING BY "FIRST-CLASS MAIL"


Attorney Docket No. : 202.8
Serial No. : 10/087,929
Applicant(s) : Clarence N. Ahlem, et al.
For : Blood Cell Deficiency Treatment Method
Attorney : Daryl D. Muenchau, Reg. No. 36,616
Date of Deposit : August 09, 2004

I hereby certify that the accompanying

Transmittal (in duplicate); Information Disclosure Statement (Form PTO-1449 – 37 references); and Return Postage Prepaid Postcard

are being deposited with the United States Postal Service "First-Class Mail" service on the date indicated above and are addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450


Brenda J. Mannon-Freeman



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.8APPLICATION NO.
10/087,929SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Ahlem, et al.FILING DATE
3/1/02GROUP
1615

USE SEVERAL SHEETS IF NECESSARY

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,667,299 B1	12/23/03	Ahlem et al.			
	3,631,033	12/28/71	Nathansohn et al.			
	3,264,326	08/02/66	Clark et al			
	4,424,218	01/03/84	Deraedt et al			
	6,046,185	04/04/00	Burgoyne et al			
	6,635,629 B2	10/21/03	Raymond et al			
	6,706,701 B1	03/16/04	Burgoyne et al			
	4,395,408	07/26/83	Torelli et al			
	5,292,730	03/08/94	Lardy			
	3,780,073	12/18/73	Shroff			
	4,118,488	10/03/78	Philippon et al			
	5,198,432	03/30/93	Fariss			
	5,292,730	03/08/94	Lardy			
	5,583,126	12/10/96	Daynes et al.			
	5,593,981	01/14/97	Labrie			
	5,885,997	03/23/99	Pauza et al			
	5,888,534	03/30/99	El-Rashidy et al			
	5,955,455	09/21/99	Labrie			
	5,739,136	04/14/98	Ellinwood, Jr., et al.			


U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL	PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.8APPLICATION NO.
10/087,929SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Ahlem, et al.FILING DATE
3/1/02GROUP
1615

USE SEVERAL SHEETS IF NECESSARY

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	PUB. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 97/34871	09/25/97	PCT				
	WO 97/37662	03/19/97	PCT				
	WO 97/37664	10/16/97	PCT				
	WO 97/40062	03/26/97	PCT				
	WO 98/02450	07/11/97	PCT				
	WO 99/25333	11/19/97	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Jones, et al, "Steroids and Steroidases. 10. Studies on some potentially antitumor active androstane compounds containing C-17 nitrogen mustard functions", <i>J of Med Chem</i> , Vol 14 (9), pp. 827-33 (1971)
	Arth, G., et al., "Steroidal androgen biosynthesis inhibitors", <i>J of Med Chem</i> , Vol 14 (8), pp. 675-79 (1971)
	Yagishita, K., "Studies on antimicrobial activities and aminosteroids - II", <i>Bull. Coll. Agr. & Vet. Med., Nihon Univ.</i> , No. 28, pp. 8 - 17 (1971)
	Pettit, G., et al, "Structural biochemistry. IV. 3 β -hydroxy-17 β -(L-prolyl)amino-androst-5-ene", <i>Canadian J of Chem</i> , Vol. 45, pp. 501 - 07 (1967)
	Navarro, J., et al, "Androgen therapy for anemia in elderly uremic patients", <i>Intl Urology and Nephrology</i> , 32, pp. 549-57 (2001)
	Whitnall, M., et al, "In vivo radioprotection by 5-androstenediol: Stimulation of the innate immune system", <i>Radiation Research</i> , 156, pp. 283-93 (2001)
	Byron, J., "Nature of the erythropoietin-independent response of CFU-S to steroids", <i>Exp. Hematol.</i> , 8, pp. 160-67 (1980)
	Levere, R., et al, "Steroid metabolites and the control of hemoglobin synthesis", <i>Bull. NY Acad. Med</i> , Vol. 50 (5), pp. 563-75 (1974)
	Fisher, J., et al, "Androgens and erythropoiesis", <i>Israel J. Med. Sci.</i> , 7, pp. 892-900 (1971)
	Nema, S., et al, "Excipients and their use in injectable products", <i>PDA J of Pharm Sci & Tech</i> , Vol. 51(4), pp. 166-171 (1997)
	Ben-Nathan, et al, "Dehydroepiandrosterone protects mice inoculated with west Nile virus and exposed to cold stress", <i>J. Med. Virol.</i> , 38, pp. 159-66 (1992)
	Carr, D., "Increased levels of IFN- γ in the trigeminal ganglion correlate with protection against HSV-1-induced encephalitis following subcutaneous administration with androstenediol", <i>J. of Neuroimmunology</i> , 89, pp. 160-87 (1998)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	